Needham & Company Remains Bullish on Cempra (CEMP) Following Meetings

Needham & Company reiterated a Buy rating and $48.00 price target on Cempra, Inc. (NASDAQ: CEMP) after hosting an investor and analyst meeting.

Analyst Alan Carr commented, "Cempra hosted an investor and analyst mtg yesterday in NYC. Several KOLs presented views on target indication Community Acquired Bacterial Pneumonia (CABP) and role of solithromycin (Solithera). High macrolide resistance and consequences of increased use of fluoroquinolones (safety profile and C. difficile) were cited as concerns. KOL panel lamented that physicians are forced to either over-treat (w/ fluoroquinolone) or under-treat (w/ macrolide) and viewed Solithera as a helpful solution. Cempra Phase 3 development program positioned Solithera as an antibiotic with the safety profile of a macrolide and efficacy of a fluoroquinolone."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $18.56 yesterday.

You May Also Be Interested In

• SK Hynix (SKHY) PT Raised to $220 at Needham
• Needham Reiterates Buy Rating on Veeva Systems (VEEV)
• Private Bancorp of America (PBAM) PT Raised to $105 at DA Davidson